Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
18.43
-0.20 (-1.10%)
At close: Nov 28, 2025, 1:00 PM EST
18.80
+0.38 (2.04%)
After-hours: Nov 28, 2025, 4:35 PM EST
Immunome Stock Forecast
Stock Price Forecast
The 8 analysts that cover Immunome stock have a consensus rating of "Strong Buy" and an average price target of $25.75, which forecasts a 39.76% increase in the stock price over the next year. The lowest target is $18 and the highest is $33.
Price Target: $25.75 (+39.76%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Immunome stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 4 | 4 | 4 |
| Buy | 4 | 4 | 5 | 5 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Maintains $25 → $33 | Buy | Maintains | $25 → $33 | +79.10% | Nov 17, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +41.11% | Sep 22, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +41.11% | Sep 5, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +35.69% | Aug 25, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Initiates $18 | Buy | Initiates | $18 | -2.31% | Aug 22, 2025 |
Financial Forecast
Revenue This Year
7.69M
from 9.04M
Decreased by -14.99%
Revenue Next Year
14.25M
from 7.69M
Increased by 85.36%
EPS This Year
-2.18
from -5.00
EPS Next Year
-2.45
from -2.18
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.1M | 43.8M | |||
| Avg | 7.7M | 14.2M | |||
| Low | 6.8M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 44.5% | 469.7% | |||
| Avg | -15.0% | 85.4% | |||
| Low | -25.2% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.93 | -1.95 | |||
| Avg | -2.18 | -2.45 | |||
| Low | -2.35 | -2.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.